Theriva Biologics Approves Stock Plan Increase, Elects Directors

What Happened

• Theriva Biologics, Inc. (TOVX) filed an 8‑K reporting results of its August 3, 2026 Annual Meeting. Stockholders approved Amendment No. 4 to the 2020 Stock Incentive Plan, increasing the plan reserve from 4,500,000 shares to 6,500,000 shares.
• Shareholders re-elected four directors to serve until the next annual meeting: Jeffrey J. Kraws, Steven A. Shallcross, John Monahan, and Jeffrey Wolf. The company also reported ratification of BDO USA, P.C. as its independent registered public accounting firm for 2026.

Key Details

• Stock incentive plan increase: authorized shares raised from 4,500,000 to 6,500,000 (Amendment No. 4).
• Director election vote totals:
  • Jeffrey J. Kraws: For 4,034,594; Withheld 2,021,707; Broker non‑votes 10,823,826
  • Steven A. Shallcross: For 4,030,358; Withheld 2,025,943; Broker non‑votes 10,823,826
  • John Monahan: For 4,003,454; Withheld 2,052,847; Broker non‑votes 10,823,826
  • Jeffrey Wolf: For 4,030,997; Withheld 2,025,304; Broker non‑votes 10,823,826
• Auditor ratification (Proposal 2): BDO USA, P.C. ratified with 14,570,613 For, 2,053,033 Against, and 256,481 Abstentions.

Why It Matters

• The plan increase gives the company more shares to grant for employee, director, and consultant equity awards, which can affect future dilution for existing shareholders.
• Re‑electing the same directors maintains board continuity and governance stability.
• Ratifying the auditor preserves accounting continuity for 2026.
• The filing contains no new financial results; investors should watch for future equity grants, potential dilution disclosures, and any related compensation details in upcoming filings.